Familial hypercholesterolaemia: identification and management

do not smoke should be strongly discouraged from starting because of their already greatly increased risk of coronary heart disease. [2008] 1.3.2.14 People with FH who smoke should be advised that, because of their already greatly increased risk of coronary heart disease, they should stop. [2008] 1.3.2.15 Healthcare professionals should offer people who want to stop smoking support and advice, and referral to an intensive support service, in line with NICE guidance on smoking cessation. [2008] 1.3.2.16 People with FH who are unwilling or unable to accept a referral to an intensive support service should be offered pharmacotherapy in line with NICE guidance on nicotine replacement therapy and bupropion, and varenicline. See NICE guidance on smoking cessation, including NICE's technology appraisal guidance on varenicline for smoking cessation. [2008] 1.3.3 Specialist treatment LDL-lowering apheresis 1.3.3.1 Healthcare professionals should consider offering LDL apheresis for the treatment of adults and children and young people with homozygous FH (see recommendations 1.1.8 and 1.1.16). The timing of initiation of LDL apheresis should depend on factors such as the person's response to lipid-modifying drug therapy and presence of coronary heart disease. [2008] 1.3.3.2 In exceptional instances (such as when there is progressive, symptomatic coronary heart disease,
